Impact of Ad Exposure Frequency on Perception and Mental Processing of Risk and Benefit Information in Direct-To-Consumer Prescription Drug Ads (Cognitive Interviews)

Data to Support Drug Product Communications as Used by the Food and Drug Administration

OMB: 0910-0695

IC ID: 214412

Information Collection (IC) Details

View Information Collection (IC)

Impact of Ad Exposure Frequency on Perception and Mental Processing of Risk and Benefit Information in Direct-To-Consumer Prescription Drug Ads (Cognitive Interviews) CDER
 
New
 
Voluntary
 

Document Type Form No. Form Name Instrument File URL Available Electronically? Can Be Submitted Electronically? Electronic Capability
Other-Questionnaire QUESTIONNAIRE 12-10-14.docx No   Paper Only

Health Consumer Health and Safety

 

498 0
   
Individuals or Households
 
   0 %

  Approved Program Change Due to New Statute Program Change Due to Agency Discretion Change Due to Adjustment in Agency Estimate Change Due to Potential Violation of the PRA Previously Approved
Annual Number of Responses for this IC 498 0 498 0 0 0
Annual IC Time Burden (Hours) 50 0 50 0 0 0
Annual IC Cost Burden (Dollars) 0 0 0 0 0 0

Title Document Date Uploaded
Justification Memo for Generic Clearance 0695 Justification Memo for generic clearance 12-10-14.doc 12/23/2014
Consent Form CONSENT FORM 12-10-14.docx 12/23/2014
Cognitive Interview Guide COGNITIVE INTERVIEW GUIDE 12-10-14.docx 12/23/2014
Cognitive Testing Guide COGNITIVE TESTING GUIDE 12-10-14.docx 12/23/2014
            Blank fields in records indicate information that was not collected or not collected electronically prior to July 2006.

© 2024 OMB.report | Privacy Policy